醫藥合約銷售外包市場－全球產業規模、佔有率、趨勢、機會及預測（按服務、治療領域、地區及競爭格局分類，2021-2031年）

全球醫藥外包市場預計將從 2025 年的 76 億美元成長到 2031 年的 106.3 億美元，複合年成長率為 5.75%。

在這個領域，包括招募、培養和管理銷售團隊在內的銷售職能外包給第三方供應商，由他們負責向醫療保健專業人員推廣藥品。該市場的主要促進因素是製造商需要將固定商業成本轉化為可變成本，以及在產品上市和專利到期等關鍵節點快速擴充性的需求。此外，外包使這些公司能夠將資金集中投入其核心競爭優勢：創新。根據歐洲製藥工業協會聯合會 (EFPIA) 的報告，2023 年歐洲以研發為基礎的製藥業預計將在研發方面投入 500 億歐元，這凸顯了最佳化商業支出的財務壓力。

儘管存在這些成長要素，但由於不同司法管轄區嚴格的監管合規要求，市場仍面臨許多挑戰。合約銷售組織必須遵守複雜的法律體制涵蓋資料隱私和推廣倫理，即使是輕微的違規行為也可能給製藥贊助商帶來嚴重的聲譽損害和經濟處罰。因此，儘管外包的策略優勢顯而易見，但與嚴格遵守各項國際法規相關的營運風險仍是市場擴張的一大挑戰。

市場促進因素

商業成本模式從固定成本轉向變動成本的轉變是全球醫藥合約銷售外包市場的關鍵促進因素。面對專利到期和研發（R&D）巨額資金需求，製藥公司迫切需要最佳化損益表，他們發現維持一支傳統的、龐大的、永久性的內部銷售團隊在財務上是不永續的。外包使製造商能夠將這些固定的人員成本轉化為靈活的變動成本，從而能夠快速擴展銷售團隊以滿足產品生命週期的需求。 Fierce Biotech 2025 年 1 月的報告清楚地闡述了這種策略重組，該報告指出，2024 年大型製藥企業報告的裁員輪次數量同比成長了 281%。這標誌著整個產業正在轉向更精簡的內部結構和外部夥伴關係。

同時，隨著越來越多的公司尋求能夠創建混合互動環境的供應商，先進的數位化和全通路銷售技術的整合正在重塑市場格局。現代銷售策略需要將線上和線下互動無縫融合，才能有效觸及醫療保健專業人員 (HCP)，而他們對聯繫的選擇也越來越挑剔。合約銷售組織 (CSO) 在提供這種複雜模式所需的數位基礎設施和技術負責人方面至關重要。根據 Veeva Systems 於 2025 年 5 月發布的《Veeva Pulse Field Trends Report》，到 2024 年，美國 HCP 的就診率將下降至 45%，這凸顯了 CSO 提供的數位化連結互動策略的重要性。這種需求也反映在財務表現上。例如，IQVIA Holdings 截至 2025 年 2 月的年度報告顯示，其合約銷售和醫療解決方案部門預計 2024 年的收入將達到 7.18 億美元，這為其在業務外包能力方面的大量投資提供了支持。

市場挑戰

不同司法管轄區嚴格的監管合規要求對全球醫藥合約銷售外包市場的擴張構成重大障礙。這種複雜性直接阻礙了市場成長，抵消了外包的關鍵優勢：速度和靈活性。當合約銷售機構 (CSO) 必須應對圍繞資料隱私和推廣倫理的複雜框架時，銷售團隊的部署會被顯著延遲。因此，CSO 被迫將大量資源從實際銷售活動轉移到法律諮詢和合規培訓，這增加了營運成本，並減少了通常為醫藥贊助商帶來的財務收益。

這種日益嚴格的監管環境迫使企業採取防禦性營運策略，減緩了它們掌握新機會的能力。例如，處方藥行為準則管理局 (PMCPA) 報告稱，2024 年共收到 264 起關於潛在違反行業準則的申訴。如此巨大的監管挑戰要求企業維持複雜的內部控制結構以降低風險。管理這些持續的合規義務所需的資源彙整限制了供應商快速擴張業務的能力，最終阻礙了市場加速成長的潛力。

市場趨勢

全球醫藥合約銷售外包市場正經歷著向專注於腫瘤和罕見疾病領域的專業團隊的顯著轉變。隨著藥物研發管線從基層醫療轉向複雜的高價值治療方法，對普通銷售負責人的需求正被能夠解讀複雜臨床數據和健保報銷環境的高素質專家所取代。製藥公司正利用合約銷售組織（CSO）快速部署這些專業領域的專家，而無需承擔設立永久性專業部門所帶來的長期營運成本。這一趨勢的驅動力在於上市產品的複雜性日益增加。根據美國食品藥物管理局（FDA）於2025年1月發布的《2024年新藥認證年度報告》，2024年核准的新藥中，52%將用於治療罕見疾病或孤兒藥，因此，由專業合約銷售組織提供的科學專業知識和商業性支持至關重要。

同時，醫藥學術專員(MSL) 和醫學事務外包業務的日益普及正在改變醫療服務提供者的格局。醫療專業人員越來越需要比傳統推廣互動更深入的科學交流，這迫使企業將商業性銷售和醫學教育分開，以維護信譽和市場准入。首席科學官 (CSO) 正在積極應對這項挑戰，他們賦予外包醫學事務團隊在產品商業性前與關鍵意見領袖 (KOL) 互動的能力。這種早期科學互動對於商業性成功至關重要。根據 Veeva Systems 於 2025 年 5 月發布的《Veeva Pulse 現場趨勢報告》，上市前現場醫學教育可使產品上市後前六個月的治療採納率提高 50%，這進一步凸顯了外包醫學團隊作為確保市場滲透戰略要素的重要性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球醫藥合約銷售外包市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按服務類型（面對面推廣（銷售團隊、重點客戶管理、職缺管理）、非面對面推廣（電話推銷、互動式電子推銷、客戶服務、醫藥學術專員、病人參與服務等））
  • 依治療領域（循環系統疾病、腫瘤、代謝性疾病、神經系統疾病、整形外科疾病、感染疾病、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美醫藥合約銷售外包市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲醫藥合約銷售外包市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區醫藥合約銷售外包市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲醫藥合約銷售外包市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲醫藥合約銷售外包市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球醫藥合約銷售外包市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Ashfield（UDG Healthcare plc）
• inVentiv Health, Inc.（Syneos Health）
• Granard Pharmaceutical Sales & Marketing
• Vanguard Pharma, Inc.
• GTS Solution
• QFR Solutions
• Pharmaforce Ireland Ltd.
• Sales Focus, Inc.
• Amplity Health
• PharmaLex GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pharmaceutical Contract Sales Outsourcing Market is projected to expand from USD 7.60 Billion in 2025 to USD 10.63 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 5.75%. This sector involves the delegation of sales functions-including the recruitment, training, and management of sales teams-to third-party providers responsible for promoting medicinal products to healthcare professionals. The market is primarily driven by the necessity for manufacturers to transform fixed commercial costs into variable expenses and the requirement for rapid scalability during critical events such as product launches or patent expirations. Furthermore, outsourcing allows these companies to channel capital toward their core competency of innovation, a priority evidenced by the European Federation of Pharmaceutical Industries and Associations' report that the research-based pharmaceutical industry invested an estimated €50,000 million in R&D in Europe in 2023, highlighting the financial pressure to optimize commercial expenditures.

Despite these growth drivers, the market faces significant impediments due to the rigorous demand for regulatory compliance across diverse jurisdictions. Contract sales organizations are required to navigate complex legal frameworks governing data privacy and promotional ethics, where even minor infractions can result in severe reputational damage and financial penalties for the pharmaceutical sponsor. Consequently, while the strategic benefits of outsourcing are clear, the operational risks associated with maintaining strict adherence to varying international regulations remain a substantial challenge for market expansion.

Market Driver

The shift from fixed to variable commercial cost models serves as a primary catalyst for the Global Pharmaceutical Contract Sales Outsourcing Market. Faced with intensifying pressure to optimize Profit and Loss (P&L) statements amid patent cliffs and high capital requirements for R&D, pharmaceutical companies are finding the traditional maintenance of large, permanent internal sales forces financially unsustainable. Outsourcing enables manufacturers to convert these fixed personnel liabilities into flexible variable expenses, allowing for the rapid scaling of sales teams in alignment with product lifecycle needs. This strategic restructuring is highlighted by a January 2025 report from Fierce Biotech, which noted that the number of layoff rounds reported by large pharmaceutical companies surged by 281% in 2024 compared to the prior year, indicating a decisive industry-wide move toward leaner internal structures and external partnerships.

Simultaneously, the market is being reshaped by the integration of advanced digital and omnichannel sales technologies, as companies seek providers capable of navigating a hybrid engagement landscape. Modern sales strategies necessitate a seamless combination of in-person and virtual interactions to effectively reach healthcare professionals (HCPs) who are becoming increasingly selective regarding access. Contract sales organizations are essential in supplying the digital infrastructure and tech-savvy representatives required for these complex models. According to the 'Veeva Pulse Field Trends Report' by Veeva Systems in May 2025, HCP access in the U.S. fell to 45% in 2024, emphasizing the critical need for the digitally connected engagement strategies offered by CSOs. This demand is reflected in financial results, such as IQVIA Holdings Inc.'s February 2025 Annual Report, which revealed that their Contract Sales & Medical Solutions segment generated $718 million in revenue for 2024, underscoring the significant investment in outsourced capabilities.

Market Challenge

The rigorous demand for regulatory compliance across varying jurisdictions acts as a formidable barrier to the expansion of the Global Pharmaceutical Contract Sales Outsourcing Market. This complexity directly hinders growth by neutralizing the primary benefits of outsourcing, specifically speed and agility. When Contract Sales Organizations (CSOs) are required to navigate intricate frameworks regarding data privacy and promotional ethics, the deployment of sales teams is significantly delayed. Consequently, CSOs must divert substantial resources from actual sales execution toward legal counsel and compliance training, which increases operational costs and diminishes the financial advantages typically afforded to pharmaceutical sponsors.

This environment of heightened scrutiny forces organizations to adopt a defensive operational posture, thereby slowing their ability to capitalize on new opportunities. For instance, the Prescription Medicines Code of Practice Authority (PMCPA) reported receiving 264 complaints regarding potential breaches of industry codes in 2024. Such a high volume of regulatory challenges necessitates that CSOs maintain elaborate internal governance structures to mitigate risk. The resource intensity required to manage these ongoing compliance obligations limits the capacity of providers to scale operations rapidly, ultimately stalling the market's potential for accelerated growth.

Market Trends

The Global Pharmaceutical Contract Sales Outsourcing Market is increasingly characterized by a shift toward specialized teams focused on oncology and rare diseases. As pharmaceutical pipelines move away from primary care blockbusters in favor of complex, high-value therapies, the demand for generalist sales representatives is being replaced by a need for highly trained professionals capable of discussing intricate clinical data and reimbursement landscapes. Pharmaceutical sponsors are leveraging Contract Sales Organizations (CSOs) to rapidly deploy these niche experts without the long-term overhead associated with permanent specialized units. This trend is driven by the rising volume of complex market entrants; according to the '2024 New Drug Therapy Approvals Annual Report' by the U.S. Food and Drug Administration in January 2025, 52% of novel drugs approved in 2024 were for rare diseases or orphan indications, necessitating the scientifically literate commercial support that specialized CSOs provide.

Concurrently, the expansion of Medical Science Liaison (MSL) and Medical Affairs outsourcing is reshaping the provider landscape. Healthcare professionals are increasingly demanding deeper scientific exchange rather than traditional promotional interactions, compelling companies to separate commercial sales from medical education to maintain credibility and access. CSOs are responding by offering outsourced Medical Affairs teams capable of engaging Key Opinion Leaders (KOLs) well ahead of a product's commercial release. This early scientific engagement is vital for commercial success; the 'Veeva Pulse Field Trends Report' from Veeva Systems in May 2025 found that pre-launch field medical education improved treatment adoption by 50% during the first six months of a launch, driving a strategic reliance on outsourced medical teams to secure market uptake.

Key Market Players

• Ashfield (UDG Healthcare plc)
• inVentiv Health, Inc. (Syneos Health)
• Granard Pharmaceutical Sales & Marketing
• Vanguard Pharma, Inc.
• GTS Solution
• QFR Solutions
• Pharmaforce Ireland Ltd.
• Sales Focus, Inc.
• Amplity Health
• PharmaLex GmbH

Report Scope

In this report, the Global Pharmaceutical Contract Sales Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Contract Sales Outsourcing Market, By Service

• Personal Promotion (Promotional Sales Team, Key Account Management, Vacancy Management)
• Non-personal Promotion (Tele-detailing, Interactive E-detailing, Customer Service, Medical Science Liaisons, Patient Engagement Services, Others)

Pharmaceutical Contract Sales Outsourcing Market, By Therapeutic Area

• Cardiovascular Disorders
• Oncology
• Metabolic Disorders
• Neurology
• Orthopedic Diseases
• Infectious Diseases
• Others

Pharmaceutical Contract Sales Outsourcing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Contract Sales Outsourcing Market.

Available Customizations:

Global Pharmaceutical Contract Sales Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Contract Sales Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Personal Promotion (Promotional Sales Team, Key Account Management, Vacancy Management), Non-personal Promotion (Tele-detailing, Interactive E-detailing, Customer Service, Medical Science Liaisons, Patient Engagement Services, Others))
  • 5.2.2. By Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Pharmaceutical Contract Sales Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Pharmaceutical Contract Sales Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Pharmaceutical Contract Sales Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa Pharmaceutical Contract Sales Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Therapeutic Area

10. South America Pharmaceutical Contract Sales Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmaceutical Contract Sales Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ashfield (UDG Healthcare plc)
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. inVentiv Health, Inc. (Syneos Health)
• 15.3. Granard Pharmaceutical Sales & Marketing
• 15.4. Vanguard Pharma, Inc.
• 15.5. GTS Solution
• 15.6. QFR Solutions
• 15.7. Pharmaforce Ireland Ltd.
• 15.8. Sales Focus, Inc.
• 15.9. Amplity Health
• 15.10. PharmaLex GmbH

16. Strategic Recommendations

17. About Us & Disclaimer